Combined CAR-T therapy after stem cell transplant for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether combining CAR-T cell therapy with a stem cell transplant can help treat multiple myeloma. It is for patients who have already had chemotherapy but still have some signs of disease or high-risk factors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with multiple myeloma.
- Your cancer has shrunk after four rounds of first-line chemotherapy, but you still have some signs of it, or you had a complete response but have high-risk features.
- Your liver and other organs are working well enough, and you are healthy enough for a stem cell transplant.
- You are not pregnant, do not have active infections like HIV or hepatitis, and can give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares standard stem cell transplant (ASCT) versus ASCT followed by a single infusion of your own immune cells engineered to attack myeloma cells (anti-BCMA CAR-T). It is for people who are newly diagnosed and eligible for a transplant.
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
This trial tests a new kind of CAR-T cell therapy (called APRIL-BAFF-Bicephali CAR-T) for people with multiple myeloma that has come back or not responded to treatment. It aims to see if this therapy is safe and can help when other treatments have stopped working.
This trial tests combining CAR-T cell therapy with a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to see if this approach can help when other treatments have failed.
This trial tests whether giving BCMA-targeting CAR-T cells after a stem cell transplant can help treat newly diagnosed multiple myeloma. It is for people who are healthy enough for both procedures.
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.